Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988530 · ClinicalTrials.gov registry record · Phase 3
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
A Phase 3 study, sponsored by Repurposed Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
NCT03988530 is a Phase 3 study that has completed, run by Repurposed Therapeutics. The registered enrollment target is 98 participants.
The verdict
NCT03988530, a Phase 3 study, has completed, sponsored by Repurposed Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With Open-Label Follow-Up
Interventions
- DRUG Scopolamine
- OTHER Placebo Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988530
The ClinicalTrials.gov registry entry for NCT03988530 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Scopolamine is the first listed.
NCT03988530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03988530 about?
NCT03988530 is a clinical study titled "Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects". A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With Open-Label Follow-Up
What is the current status of trial NCT03988530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2019-06-07. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT03988530?
The interventions under investigation include: Scopolamine (DRUG), Placebo Nasal Gel (OTHER).
Who is sponsoring clinical trial NCT03988530?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.